TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04376463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Aminoacid
Description: It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Aminoacid
Description: It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
Study: NCT00777491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant cisplatin
Description: 70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant cisplatin
Description: 70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
Study: NCT04371731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care4todayheart failure platform
Description: Platform allowing patients to enter information about their health at home, namely weight and BP and medications
Study: NCT00767156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega7 Sea Buckthorn Oil Cream
Description: The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base cream
Description: The subjects use the base cream on the face, twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBA24 Sea Buckthorn Oil Capsule
Description: The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
Study: NCT00767156

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBA24 Sea Buckthorn Oil Capsule
Description: Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
Study: NCT03364933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary intensivist and nurses
Description: Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings.
Study: NCT04567823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smoothie with microalgae
Description: Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smoothie with microalgae
Description: Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smoothie with microalgae
Description: Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Study: NCT03063242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
Study: NCT02654704

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
Study: NCT02334332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational brochure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Receive standard post-operative care
Study: NCT03038087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSE Device
Description: The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device.
Study: NCT05932498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip surgery
Description: Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively.
Study: NCT03029117

Intervention type: PROCEDURE
Intervention: correction of rheumatic valve lesions
Study: NCT00864799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
Study: NCT02812771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinaconazole
Description: Solution
Study: NCT06355830

Intervention type: DIAGNOSTIC_TEST
Intervention: Orthoptic assessment (Outcome measure)
Description: The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
Study: NCT01029392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000iu once a day
Study: NCT00869661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 or 48 weeks
Study: NCT05932498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip surgery
Description: Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively.
Study: NCT03063242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be drawn at baseline and during each subsequent visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be drawn at baseline and during each subsequent visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be drawn at baseline and during each subsequent visit
Study: NCT05040048

Intervention type: OTHER
Intervention: Clinical, biological and imaging assessment

Intervention type: OTHER
Intervention: Clinical, biological and imaging assessment
Study: NCT04066959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System (MES)
Description: MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System (MES)
Description: MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System (MES)
Description: MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
Study: NCT00434278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Study: NCT04066959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System (MES)
Description: MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Description: A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Description: A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
Study: NCT00434278

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Study: NCT03095508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angal S, topical spray [Menthol]
Description: 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
Study: NCT04066959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Description: A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Description: A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders (TXT)
Description: TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders (TXT)
Description: TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders (TXT)
Description: TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
Study: NCT01051661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Description: Intramuscular injection, one or two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Description: Intramuscular injection, one or two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Description: Intramuscular injection, one or two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Description: Intramuscular injection, one or two doses
Study: NCT03095508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTI-ANGIN® FORMULA, topical metered spray
Description: 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution
Study: NCT00611832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple P Media Series -- Standard Information-Only version
Description: 10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
Study: NCT01051661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, one dose
Study: NCT02259803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine fixed-dose combination (FDC) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study: NCT04728425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunoglobulin (SCIG)
Description: 20% subcutaneous immunoglobulin
Study: NCT00611832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Media Series -- Enhanced Behavior Activation version
Description: 10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
Study: NCT02777879

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
Study: NCT03569683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External bevel gingivectomy
Description: External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser Biostimulation
Description: After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
Study: NCT04728425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)
Description: 10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
Study: NCT00869661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 48 weeks
Study: NCT03569683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Gengigel) topical application.
Description: After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal gel (Hiora SG) topical application
Description: After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)